Evidence map›Paper›PMID 38170393›Full record

ArticlePulmonary therapy2024

Successful Use of Easyhaler

Annette Kainu, Ville A Vartiainen, Witold Mazur, Hanna Hisinger-Mölkänen, Federico Lavorini, Christer Janson, Martin Andersson

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Pulmonary therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01424137 nacompletednot on this map

Inspiratory Flow Parameters With Placebo Dry Powder Inhalers, Easyhaler and Diskus; an Open, Randomised, Multicentre Study in Patients With Asthma or COPD

TypeinterventionalSponsorOrion Corporation, Orion PharmaRan2011 to 2011Enrolled227ConditionsAsthma, Chronic Obstructive Pulmonary DiseaseArmsEasyhaler type A, Easyhaler type B, Diskus inhaler
NCT04147572 nacompletednot on this map

Inspiratory Flow Parameters With Placebo Tiotropium Easyhaler® and Placebo Spiriva® Capsule Via HandiHaler® in Patients With COPD and in Healthy Volunteers. Substudy: Easyhaler® and HandiHaler® Usability Study in Patients With COPD

TypeinterventionalSponsorOrion Corporation, Orion PharmaRan2019 to 2020Enrolled200ConditionsHealthy Volunteer, COPDArmsPlacebo Tiotropium inhalation powder type A, Placebo Spiriva capsule, Placebo Tiotropium inhalation powder type B, Substudy Placebo Tiotropium Easyhaler, Substudy Placebo Spiriva® via HandiHaler
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Annette KainuMedzilla Oy, Helsinki, Finland.
Ville A VartiainenIndividualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Witold MazurHeart and Lung Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Hanna Hisinger-MölkänenGlobal Medical Affairs, R&D, Orion Pharma, Espoo, Finland. hanna.hisinger-molkanen@helsinki.fi.ORCID http://orcid.org/0000-0003-2293-0279
Federico LavoriniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Christer JansonDepartment of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.
Martin AnderssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
University of Helsinki · FIHelsinki Metropolia University of Applied Sciences · FIKarolinska Institutet · SEOrion Corporation (Finland) · FIUniversity of Florence · ITUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is increasing pressure to use environmentally friendly dry powder inhalers (DPI) instead of pressurized metered-dose inhalers (pMDI). However, correct inhalation technique is needed for effective inhaler therapy, and there is persistent concern whether patients with chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory effort to use DPIs successfully. The aims of this study were to find clinical predictors for peak inspiratory flow rate (PIF) and to assess whether patients with COPD had difficulties in generating sufficient PIF with a high resistance DPI.

methodsPooled data of 246 patients with COPD from previous clinical trials was analyzed to find possible predictors of PIF via the DPI Easyhaler (PIFEH) and to assess the proportion of patients able to achieve an inhalation flow rate of 30 l/min, which is needed to use the Easyhaler successfully.

resultsThe mean PIF was 56.9 l/min and 99% (243/246) of the study patients achieved a PIF ≥ 30 l/min. A low PIF was associated with female gender and lower forced expiratory volume in 1 s (FEV1), but the association was weak and a statistical model including both only accounted for 18% of the variation seen in PIFEH.

conclusionsBased on our results, impaired expiratory lung function or patient characteristics do not predict patients' ability to use DPIs in COPD; 99% of the patients generated sufficient PIFEH for successful dose delivery. Considering the targets for sustainability in health care, this should be addressed as DPIs are a potential option for most patients when choosing the right inhaler for the patient.

trial registrationTwo of three included trials were registered under numbers NCT04147572 and NCT01424137. Third trial preceded registration platforms and therefore, was not registered.

Indexed as

COPDDPIDry powder inhalerInhalationInhalerTechnique

Identifiers

PMID38170393
PMCPMC10881915
OpenAlexW4390570985

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.